Feb 04, 2020 - The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Jan 30, 2020 - Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Jan 29, 2020 - It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Jan 28, 2020 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jan 28, 2020 - SNY vs. NVO: Which Stock Is the Better Value Option?
Jan 28, 2020 - The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
Jan 27, 2020 - Top Stock Analyst Reports for Merck, Broadcom & Sanofi
Jan 21, 2020 - Is Sanofi (SNY) a great pick from the value investor's perspective right now? Read on to know more.
Jan 16, 2020 - The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Jan 13, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.